04/25/2026
"For many patients, it feels like for the first time their body isn't fighting against them." Sarah H. Finn, MD, section chief of Obesity Medicine at Dartmouth Health, says about GLP-1s.
Ozempic, Wegovy, and Zepbound, which belong to a group of drugs called GLP-1 receptor agonists, are showing promise in helping manage several long-term health problems beyond diabetes and obesity, including liver disease, chronic kidney disease, obstructive sleep apnea, and possibly addiction.
While these results are a potential gamechanger, these drugs can also be expensive, cause side effects, and need to be taken long-term to work best.
⬇️